This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
28


nanotimes


Companies Facts


for enabling computer chips to communicate using pulses of light instead of electrical signals, which can deliver increased performance of computing systems. http://www.youtube.com/watch?v=WBkvzubVyOY


I


llumina, Inc. (NASDAQ: ILMN) announced MiSeq™, a low-cost personal sequencing system that pro-


vides individual researchers a platform with rapid turnaround time, unmatched accuracy, and radically improved ease of use. Leveraging the company‘s TruSeq™ sequencing chemistry, the system‘s revo- lutionary workflow offers the flexibility to go from purified DNA to analyzed data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over a day. Expected to be priced under $125,000 with individual run prices ranging from $400-$750, MiSeq will be the most affordable next- generation sequencing (NGS) platform available. Illumina expects to take initial orders for the MiSeq™ platform starting in April 2011 and anticipates ship- ping the first commercial units of MiSeq in summer 2011.


Furthermore, Illumina has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications. A key component of the acquisition is direct access to Epicentre‘s proprietary Nextera™ technology for next-generation sequencing library preparation, which greatly simplifies genetic analysis workflows and reduces time from sample preparation to an- swer.


Illumina announced preliminary revenue for the fourth quarter of 2010 of approximately $260 milli- on. This implies fiscal year 2010 revenue of appro-


ximately $901 million or annual growth of 35%. The Company also announced preliminary non-GAAP earnings per share for the fourth quarter and fiscal year 2010 between $0.28 and $0.29 and $1.05 and $1.06, respectively. The Company expects revenue growth for the full year 2011 of approximately 20% from anticipated 2010 revenue of $901 million and non-GAAP earnings per share to grow more than 30% from anticipated 2010 non-GAAP earnings per share between $1.05 and $1.06. http://www.illumina.com/miseq


I


nhibOx Ltd, based in Oxford, U.K., the specialist in novel and effective computational methods for


drug discovery, launched Scopius-5 – the world‘s largest currently available drug discovery scree- ning database and the first system to pass 100 milli- on compounds. Scopius-5 is a unique and powerful resource that will enable new levels of innovation and rigor to screening processes in drug discovery.


The Scopius-5 database platform stores many details of selected compounds, invaluable to those working in drug discovery. They include: multiple-conformati- on 3D models, shape and charge descriptors, pro- perty values and compound availability information, and/or synthetic route details. To ensure their useful- ness in discovery projects, entries are filtered against a set of drug-likeness criteria - structural and physical properties known to be common to almost all phar- maceutical compounds.


Scopius-5 consists of more than 110 million entries in three distinct sections, each enabling different approaches to lead identification and optimization studies. Scopius-5 is able to support very large-scale virtual screening studies at practical speeds because


11-01 :: December 2010 / January 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95
Produced with Yudu - www.yudu.com